Relevant bibliographies by topics / Cancer - Radiotherapy treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer - Radiotherapy treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer - Radiotherapy treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer - Radiotherapy treatment"

1

Shirai, Katsuyuki, Akiko Nakagawa, Takanori Abe, Masahiro Kawahara, Jun-ichi Saitoh, Tatsuya Ohno, and Takashi Nakano. "Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers." International Journal of Molecular Imaging 2012 (May 14, 2012): 1–9. http://dx.doi.org/10.1155/2012/609545.

Full text
Abstract:
Radiotherapy plays an important role in the treatment for thoracic cancers. Accurate diagnosis is essential to correctly perform curative radiotherapy. Tumor delineation is also important to prevent geographic misses in radiotherapy planning. Currently, planning is based on computed tomography (CT) imaging when radiation oncologists manually contour the tumor, and this practice often induces interobserver variability. F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to enable accurate staging and detect tumor extension in several thoracic cancers, such as lung cancer and esophageal cancer. FDG-PET imaging has many potential advantages in radiotherapy planning for these cancers, because it can add biological information to conventional anatomical images and decrease the inter-observer variability. FDG-PET improves radiotherapy volume and enables dose escalation without causing severe side effects, especially in lung cancer patients. The main advantage of FDG-PET for esophageal cancer patients is the detection of unrecognized lymph node or distal metastases. However, automatic delineation by FDG-PET is still controversial in these tumors, despite the initial expectations. We will review the role of FDG-PET in radiotherapy for thoracic cancers, including lung cancer and esophageal cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Barley, Victor. "Treatment of cancer." Clinical Risk 13, no. 5 (September 1, 2007): 196–99. http://dx.doi.org/10.1258/135626207781572756.

Full text
Abstract:
The second in a series of three articles. This article describes the management of cancer by surgery, radiotherapy and drugs. The beneficial and harmful effects of radiation are described, and the planning and delivery of radiotherapy are outlined. Potential errors such as incorrect or delayed diagnosis, failure to obtain informed consent, errors in planning, identification, or dose of radiation given are discussed. Chemotherapy and its side effects are explained and the potential harm from error in prescription or delivery is described.
APA, Harvard, Vancouver, ISO, and other styles
3

Asadli, Geis. "RADIOTHERAPY IN COMBINED TREATMENT OF RECURRENT STAGE 3 LARYNGEAL CANCER." International Medical Journal, no. 4 (February 26, 2020): 63–66. http://dx.doi.org/10.37436/2308-5274-2019-4-14.

Full text
Abstract:
The paper presents the treatment results performed in 250 patients with a laryngeal tumor of the third stage. The average life expectancy of these patients generally does not exceed 3−6 months. Chemotherapy is usually considered the standard treatment for the recurrence of head and neck squamous cell cancer patients, previously received radiotherapy. When prescribing the chemotherapy, a tumor regression is observed only in 10−40 % and does not virtually affect the life. Average life expectancy of these patients often varies from 5 to 9 months. The optimal total dose of radiotherapy for the treatment of inoperable recurrent and metastatic cancer was found in this reserach for imroving treatment results. The surgical protocols and techniques under discussion in this paper are certainly of a practical significance. The method for preoperative radiotherapy for larynx cancers was developed and the guidelines have been proven. Also there was proven that preoperative radiotherapy in a combined treatment of recurrent operable laryngeal cancer increases its effectiveness and does not affect postoperative period. Repeated radiotherapy for recurrent inoperable laryngeal cancer is possible only if the changes after previous radio− or combination therapy do not exceed 2 degrees. In addition, a repeated radiotherapy at a total source dose of 40−60 Gy is an effective method of palliative treatment and significantly improves the life expectancy and quality in the patients if compared with palliative chemotherapy. The method used in combination with intratumoral chemo− and radiotherapy significantly improves the efficiency of palliative treatment in the patients with recurrent regional metastasis for inoperable laryngeal cancer, in the primary tumor area, no signs of recurrence were found. Key words: laryngeal cancer, combined cancer treatment, radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Novario, Raffaele, Paola Stucchi, Lucia Perna, and Leopoldo Conte. "Radiotherapy Treatment Verification." Tumori Journal 84, no. 2 (March 1998): 144–49. http://dx.doi.org/10.1177/030089169808400209.

Full text
Abstract:
During a radiotherapy treatment, a dosimetric verification or a geometric localization can be done, in order to assess the quality of the treatment. The dosimetric verification is generally performed measuring the dose at some points inside (natural cavities) or outside the patient, and comparing it to the dose at the same points calculated and predicted by the treatment planning system. This can be done either with thermoluminescent or diodes dosimeters or with ionization chambers. The geometric localization can be done acquiring a portal image of the patient. Portal imaging can be performed either with films placed between metallic screens, or with an electronic portal imaging device such as fluoroscopic systems, solid state devices or matrix ionization chamber systems. In order to assess possible field placement errors, the portal images have to be compared with images obtained with the simulator in the same geometric conditions and/or with the digitally reconstructed radiograph (DRR) obtained with the treatment planning system. In particular, when using matrix ionization chamber systems, the portal images contain also information regarding the exit dose. This means that this kind of imaging device can be used both for geometric localization and for dosimetric verification. In this case, the exit dose measured by the portal image can be compared with the exit dose calculated and predicted by the treatment planning system. Some “in-vivo” applications of this methodology are presented.
APA, Harvard, Vancouver, ISO, and other styles
5

Radosevic-Jelic, Ljiljana, Suzana Stojanovic, and I. Popov. "Radio therapy in prostate cancer treatment." Acta chirurgica Iugoslavica 52, no. 4 (2005): 93–102. http://dx.doi.org/10.2298/aci0504093r.

Full text
Abstract:
Prostate cancer is a complex disease, with many controversial aspects of management in almost all stages of disease. The natural history of this tumor is variable and is influenced by multiple prognostic factors. Radical prostatectomy and radiotherapy are standard treatment options for disease limited to the prostate. The data in literature does not provide clear- cut evidence for the superiority of any treatment. Neo- adjuvant or adjuvant hormonal therapy improves local control and survival in locally advanced disease. The patients treated with radiotherapy would have a relatively long life expectancy, not great risk factors for radiation toxicity and a preference for radiotherapy. The advantages of radiotherapy are that it has a significant potential for cure, it is well tolerated in the majority of men especially when the modern techniques of conformal radiotherapy and intensity modulated therapy are used and it is non-invasive therapeutic options with no anesthesia risk. Expected complications like radiation cystitis, impotence and proctitis are registered in about 1% of patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Dearnaley, D. P. "Radiotherapy and hormonal treatment." European Journal of Cancer Supplements 5, no. 5 (September 2007): 177–88. http://dx.doi.org/10.1016/s1359-6349(07)70038-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rong, Yi, Li Zuo, Lu Shang, and Jose G. Bazan. "Radiotherapy treatment for nonmelanoma skin cancer." Expert Review of Anticancer Therapy 15, no. 7 (May 8, 2015): 765–76. http://dx.doi.org/10.1586/14737140.2015.1042865.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Breast cancer: tamoxifen treatment after radiotherapy." Inpharma Weekly &NA;, no. 1104 (September 1997): 18. http://dx.doi.org/10.2165/00128413-199711040-00036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Falk, Stephen. "Principles of cancer treatment by radiotherapy." Surgery (Oxford) 27, no. 4 (April 2009): 169–72. http://dx.doi.org/10.1016/j.mpsur.2009.01.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gwynne, Sarah, and John Staffurth. "Principles of cancer treatment by radiotherapy." Surgery (Oxford) 30, no. 4 (April 2012): 191–93. http://dx.doi.org/10.1016/j.mpsur.2012.01.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer - Radiotherapy treatment"

1

Cha, Kyungduck. "Cancer treatment optimization." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2008. http://hdl.handle.net/1853/22604.

Full text
Abstract:
Thesis (Ph. D.)--Industrial and Systems Engineering, Georgia Institute of Technology, 2008.
Committee Chair: Lee, Eva K.; Committee Member: Barnes, Earl; Committee Member: Hertel, Nolan E.; Committee Member: Johnson, Ellis; Committee Member: Monteiro, Renato D.C.
APA, Harvard, Vancouver, ISO, and other styles
2

Williamson, Raymond Allan. "An experimental study of the use of hyperbaric oxygen treatment to reduce the side effects of radiation treatment for malignant disease." University of Western Australia. School of Anatomy and Human Biology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0063.

Full text
Abstract:
[Truncated abstract] Therapeutic Radiation has been used for the treatment of cancer and other diseases for nearly a century. Over the past 20 years, Hyperbaric Oxygen Treatment (HBOT) has been used to assist wound healing in the prevention and treatment of the more severe complications associated with the side effects of Therapeutic Radiation Treatment (TRT). The use of HBOT is based on the premise that increased oxygen tissue tension aids wound healing by increasing the hypoxic gradient and stimulating angiogenesis and fibroblast differentiation. As it takes up to 6 months for a hypoxic state to develop in treated tissue, following radiation treatment, current recommendations for HBOT state that it is not effective until after this time. During this 6 month period, immediately following TRT, many specialized tissues in or adjacent to the field of irradiation, such as salivary glands and bone, are damaged due to a progressive thickening of arteries and fibrosis, and these tissues are never replaced. Currently, HBOT is used to treat the complications of TRT, but it would be far better if they could be prevented . . . In summary, this experimental model has fulfilled its prime objective of demonstrating that HBOT is effective in reducing the long-term side effects of therapeutic radiation treatment in normal tissue, when given one week after the completion of the radiation treatment and statistically disproves the Null Hypothesis that there is no difference in the incidence of postoperative complications or morbidity of TRT when 20 intermittent daily HBOT are started one week after completion of TRT. This project provides an extensive description of the histological process and also proposes a hypothesis for the molecular events that may be taking place.
APA, Harvard, Vancouver, ISO, and other styles
3

Wey, Mark Tao Teong. "DNA repair in bladder cancer predisposition and radiotherapy treatment response." Thesis, University of Leeds, 2012. http://etheses.whiterose.ac.uk/8087/.

Full text
Abstract:
The genetic contribution to bladder cancer risk remains undetermined, while the role of radiotherapy versus surgery in muscle-invasive bladder cancer (MIBC) treatment is hotly debated with the need for predictive biomarkers of treatment response. DNA repair pathways are involved in repairing DNA damage from carcinogens thus preventing carcinogenesis, but also form one of the 5 R’s of radiobiology for determining cancer response to radiotherapy. The aims of this project were: 1) To study the contribution of germline DNA repair gene variants, specifically rare variants (RV) and 3’-untranslated region (3’UTR) single nucleotide polymorphisms (SNP), on bladder cancer risk. 2) To investigate the predictive value of germline DNA repair gene variants and tumour DNA repair protein expression on radiotherapy outcomes in MIBC. RVs can only be identified by sequencing so a developmental multiplexed next-generation sequencing (NGS) project was undertaken, identifying two approaches, with the choice of method based on balancing costs and labour versus accuracy and data needed. Using these methods, candidate RVs were identified in the DNA repair genes, MUTYH and XPC, with XPC RVs being associated with an increased bladder cancer risk (P=0.008) independent of previously identified GWAS SNPs. Putatively functional DNA repair gene 3’UTR SNPs, PARP1 rs8679 and RAD51 rs7180135, were found to increase bladder cancer risk (P=0.05) and predict improved survival following radiotherapy (P=0.01) respectively. Multiplexed NGS of MRE11A identified rs1805363 to be predictive of survival following radiotherapy (P=0.001) but not surgery (P=0.89), and to affect MRE11A isoform expression. Tumour DNA repair protein expression of CtIP, MUTYH and XPC were not found to predict survival following radiotherapy. This study demonstrated the contribution of DNA repair gene variants in bladder cancer risk and predicting radiotherapy response. These findings could contribute to the goal of personalised medicine for targeted primary prevention, early diagnosis and treatment individualisation.
APA, Harvard, Vancouver, ISO, and other styles
4

Fokas, Emmanouil. "Targeting the PI3K/mTOR and ATK/Chk1 pathways to improve radiation efficacy for cancer therapy." Thesis, University of Oxford, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.572788.

Full text
Abstract:
The purpose of the present thesis was to better understand the effect of targeting key biological mechanisms in order to improve radiotherapy response. Two important and distinct pathways were targeted using novel agents: (1) the phosphoinoside-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway; (2) the ataxia telangiectasia-mutated-Rad3-related (ATR)/Chkl pathway. The role of the PI3K1mTOR signalling pathway in tumour radiosensitivity and tumour microerivlronment (TME) was examined using three, recently-developed signalling inhibitors obtained from Novartis Pharma: NVP-BEZ235 (dual PI3K1mTOR inhibitor), NVP-BGT226 (dual PI3K1mTOR inhibitor) and NVP-BKM120 (single PI3K inhibitor). The radiosensitising potential of NVP-BEZ235 and NVP-BGT226 was demonstrated in tumour and endothelial cells. Additionally, a thorough research into the effects ofNVP-BKM120 and NVP-BEZ235 on TME showed that oncogenic signalling inhibitors can improve vascular morphology and increase tumour oxygenation and perfusion in tumour xenograft models, resulting in improved radiation response. Furthermore, a highly potent and selective A TR inhibitor, VE-822, that was obtained from Vertex Pharmaceuticals (Europe) Ltd, was tested in pancreatic ductal adenocarcinoma (PDAC) cells and tumour xenograft models. A TR inhibition by VE-822 resulted in sensitisation of tumour cells but not normal cells to radiation and gemcitabine. Similarly, VE-822 strongly enhanced radiation- and chemoradiation-induced tumour growth delay in tumour xenograft models. Importantly, VE-822 did not potentiate radiation-induced gastrointestinal tract epithelial damage. To summarize, the impact of targeting two distinct pathways in combination with radiation and chemoradiation was explored. Inhibition of the PI3K1mTOR and ATRlChkl signalling pathways increases response of tumours to radiotherapy they and might be promising targeting strategies for cancer treatment. Our findings have considerable translational implications and future clinical trials should aim to validate these observations.
APA, Harvard, Vancouver, ISO, and other styles
5

Murray, Louise Janet. "Optimising treatment outcomes using Stereotactic Body Radiotherapy (SBRT) for prostate cancer." Thesis, University of Leeds, 2014. http://etheses.whiterose.ac.uk/8666/.

Full text
Abstract:
Aims: to optimise linear accelerator-based prostate stereotactic ablative radiotherapy (SABR) through planning studies, tumour control probability (TCP) and normal tissue complication probability (NTCP) calculations and radiation-induced second primary cancer (RISPC) risk assessment. Methods: A planning study was performed to develop a class solution for prostate SABR. A second planning study delivered boosts to dominant intra-prostatic lesions (DILs) and TCP and NTCP were calculated. A third planning study compared prostate SABR planning using flattened and flattening filter free (FFF) beams. A systematic review examined RISPC risk following prostate radiotherapy. A final study estimated RISPC risks following prostate SABR in comparison to other contemporary radiation techniques. Results: Prostate SABR was optimal using a single anterior arc which resulted in highly conformal plans, lower rectal doses and improved delivery times and monitor unit requirements for most patients. Boosting DILs resulted in small TCP increases, but the benefit was offset by increases in NTCP. SABR to the whole prostate without DIL boosting resulted in high TCP and low NTCP. Plans using flattened and FFF beams were dosimetrically similar but FFF resulted in reduced delivery times. Clinical evidence, largely based on older radiation techniques, suggests that prostate radiotherapy increases RISPC risk. Clinical evidence concerning risk following modern techniques is too immature to draw firm conclusions. The final study demonstrated that SABR techniques resulted in lower estimated RISPC risks in all organs compared to conventionally fractionated techniques, while FFF techniques reduced RISPC risks in out-of-field organs. Conclusions: Linear accelerator-based prostate SABR delivered with a single partial arc is optimal and high levels of TCP and low levels of NTCP are predicted from whole prostate SABR. FFF allows faster treatment delivery. Second malignancy risk is lower using SABR, particularly with FFF, compared to conventionally fractionated techniques. Phase III trials are required to investigate prostate SABR in practice.
APA, Harvard, Vancouver, ISO, and other styles
6

Elder, Eric Scott. "A method and treatment device for non-coplanar radiotherapy of the pancreas." Diss., Georgia Institute of Technology, 1997. http://hdl.handle.net/1853/17656.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Olausson, Kristina. "Patient experiences of the radiotherapy process and treatment." Doctoral thesis, Umeå universitet, Onkologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-127456.

Full text
Abstract:
Background Most cancer patients undergo external radiotherapy (RT) at some stage during their treatment trajectory. RT is often associated with unfamiliar procedures where the technical environment, side effects and interaction with staff seem to play a major role in the patient’s treatment experience. These experiences could sometimes lead to disruption of the treatment which may have negative consequences for the outcome. The overall aim of this thesis was to gain further knowledge about how patients experience RT and the related processes. Such knowledge is of vital importance when developing and improving care within a high-tech RT environment. Aim The overall aim of this thesis was to gain further knowledge about how patients experience RT and the related processes. Such knowledge is of vital importance when developing and improving care within a high-tech RT environment. Methods To gain further knowledge and understanding about patients experience of RT both quantitative (I, II, III) and qualitative (III, IV) methodology were used. The data in the thesis focused on patients undergoing external RT at different RT units in Sweden. Study I and II, focused on two regions, the northern region of Sweden and the region of Stockholm and Gotland.  Study III and IV were performed at eight different RT units in Sweden. Results In Study I, two types of topical agents (Calendula Weleda cream vs. Essex cream) were compared regarding reducing the risk of severe acute radiation skin reactions (ARSR). No difference in severe ARSR was found between the groups and the patients reported low levels of ARSR. In Study II, the influence of an RT unit’s psychosocial climate and treatment environment on cancer patients’ anxiety during external RT was evaluated. Data was collected (questionnaire) from 892 patients. The results showed that both the treatment environment and the psychosocial climate of the RT unit significantly impacted cancer patient anxiety levels. In Study III & IV, a questionnaire to measure the patient´s experience during external RT was developed and tested. The results showed that the RT Experience Questionnaire (RTEQ), with 23 items, was a tentatively valid and reliable instrument to measure how patients experience the RT process and the environment in the treatment room. In Study IV, written comments from the open-ended question “Is there anything else you want us to know?” in the preliminary RTEQ was analysed with qualitative content analysis. This data was abstracted into the following four major categories reflecting the experience of the RT process:  Experiences in the high tech RT environment; Understanding the RT procedures and side effects; Dealing with daily life during RT and The nurses’ role and performance. Conclusion The RT environment and the RT related processes seem to impact cancer patients, both physically and psychologically. A person-centered care approach, as well as attention to the design, both of the treatment process and the physical environment could significantly improve the patient experience and patient involvement. The results also highlight the importance of taking patient experiences into account when introducing new RT methods and techniques.
APA, Harvard, Vancouver, ISO, and other styles
8

Tse, Ka-ho, and 謝家豪. "A comparison of contralateral breast dose from primary breast radiotherapy using different treatment techniques." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206498.

Full text
Abstract:
Breast cancer is the most common cancer among women worldwide. Millions of new breast cancer cases are diagnosed every year, accounting for one-tenth of all new cancer cases. Because of the proof of equivalent efficacy between breast-conserving therapy (BCT) plus radiotherapy and mastectomy, increasing number of patients received breast irradiation during the past three decades, and radiotherapy plays a more and more important role in managing breast cancer. With the advancement of technology, the radiotherapy treatment techniques changed from conventional wedged technique to intensity modulated radiotherapy (IMRT), resulting in an improvement in the dose homogeneity. Regardless of the treatment techniques, peripheral dose to the contralateral breast is inevitable. The possibility of the peripheral dose causing contralateral breast cancer (CBC) has re-attracted the interest. However, the variation of the peripheral dose with different treatment techniques has not been well identified. Thus this study aims to compare the contralateral breast dose from the primary breast irradiation using various radiotherapy treatment techniques and types of shielding. Six treatment plans by different treatment techniques, including paired physical wedges (PW-P), a lateral physical wedge only(PW-L), paired enhanced dynamic wedges (EDW-P), a lateral enhanced dynamic wedge only(EDW-L), field-in-field tangential opposing (TO-FiF), and inverse-planned intensity modulated radiotherapy (IMRT-IP), were generated using a female Rando phantom. The phantom was treated by all plans, and 15 metal oxide semiconductor field effect transistor(MOSFET)detectors on the surface and inside the contralateral breast were utilized for measuring the contralateral breast dose for each plan. Measurement was repeated with the application of 0.2, 0.3 and 0.5cm lead sheets or 0.5 and 1cm superflab (SF) on the TO-FiF to demonstrate the effect of shielding on the contralateral breast dose. The measured contralateral breast doses were: 2.05Gy for PW-P, 1.44Gyfor PW-L, 1.51Gyfor EDW-P, 1.52Gyfor EDW-L, 1.25Gyfor TO-FiF, and 1.17Gyfor IMRT-IP, corresponding to 2.35% to 4.11% of total dose. PW-P producedthe highest contralateral breast dose while IMRT-IP producedthe lowest. For the addition of shielding, the doses were: 1.25Gy for no shielding, 0.65Gy for 0.2cm lead, 0.61Gy for 0.3cm lead, 0.49Gy for 0.5cm lead, 0.76Gy for 0.5cm SF, and 0.72Gy for 1cm SF. Lead sheet with 0.5cm thickness most effectively reduced the contralateral breast dose by 60%.All techniques showed that the surface dose was much higher than the dose at depth, and the dose dropped exponentially from the surface to the internal. Low energy radiation constitutes a large portion of the contralateral breast dose, so all types of shielding could decrease the surface dose effectively, but not the internal dose. The radiation-induced CBC risks were estimated to be about 0.77% to 1.36%. To conclude, it is important that the contralateral breast dose to patients, especially those under 45, is maintained minimal. Therefore, TO-FiF or IMRT-IP are recommended to be the treatment of choices. The used of shielding, either lead or SF, is also advisable.
published_or_final_version
Diagnostic Radiology
Master
Master of Medical Sciences
APA, Harvard, Vancouver, ISO, and other styles
9

Wu, Wing-cheung Vincent, and 胡永祥. "Dose analysis of 2-dimensional and 3-dimensional radiotherapy techniques in the treatment of nasopharyngeal carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1997. http://hub.hku.hk/bib/B31220149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

胡寶文 and Po-man Wu. "The application of the tumor control probability model of nasopharyngeal carcinoma in three dimensional conformal treatment planevaluation." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B31241232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer - Radiotherapy treatment"

1

Goddard, Maria. The costs of radiotherapy in cancer treatment. York: University of York Centre for Health Economics, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Goddard, Maria. The costs of radiotherapy in cancer treatment. York: Centre for Health Economics, University of York, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Leavell, Alice. Radiation treatment for head & neck cancer. Seattle, WA: Veterans Administration Medical Center, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pollack, Alan, and Mansoor M. Ahmed. Hypofractionation: Scientific concepts and clinical experiences. Ellicott City, MD: LumiText Publishing, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1925-, Vaeth Jerome M., and Meyer John 1949-, eds. Treatment planning in the radiation therapy of cancer. Basel: Karger, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Haas, Olivier C. L. Radiotherapy treatment planning: New system approaches. London: Springer, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

E, Nelson Charles, and Noell K. Thomas, eds. Treatment planning & dose calculation in radiation oncology. 4th ed. New York: Pergamon Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Breast cancer treatment options. Commack, N.Y: Nova Science Publishers, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

E, Nelson Charles, and Noell K. Thomas, eds. Treatment planning & dose calculation in radiation oncology. 4th ed. New York: McGraw-Hill, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

J, Heide, ed. Controversies in the treatment of lung cancer. Basel: Karger, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer - Radiotherapy treatment"

1

Dandapani, Savita V. "Biomarkers and Radiotherapy." In Cancer Treatment and Research, 223–38. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-53235-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Low, Daniel A. "MRI Guided Radiotherapy." In Cancer Treatment and Research, 41–67. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-53235-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dougherty, Michael J., and Morton M. Kligerman. "Radiotherapy of melanoma." In Cancer Treatment and Research, 355–71. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-3080-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Balogun, Onyinye, and Silvia C. Formenti. "Combining Radiotherapy and Immunotherapy." In Cancer Treatment and Research, 1–20. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-53235-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Helm, Frederick, Thomas N. Helm, and Robert A. Schwartz. "Treatment of Cutaneous Cancers by Radiotherapy." In Skin Cancer, 353–62. New York, NY: Springer New York, 1988. http://dx.doi.org/10.1007/978-1-4612-3790-7_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Darzy, Ken H., and Stephen M. Shalet. "Hypopituitarism following Radiotherapy Revisited." In Endocrinopathy after Childhood Cancer Treatment, 1–24. Basel: KARGER, 2009. http://dx.doi.org/10.1159/000207607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Arcangeli, Giorgio, Stefano Arcangeli, and Lidia Strigari. "Hypofractionation and Stereotactic Treatment: Clinical Data." In Radiotherapy in Prostate Cancer, 163–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grün, Arne. "Treatment of Clinically Involved Lymph Nodes." In Radiotherapy in Prostate Cancer, 149–51. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/174_2014_1025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schwarz, Rudolf, Oyvind Bruland, Anna Cassoni, Paula Schomberg, and Stefan Bielack. "The Role of Radiotherapy in Oseosarcoma." In Cancer Treatment and Research, 147–64. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-1-4419-0284-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Harmer, Clive, and Margaret Bidmead. "Three-dimensional planning and conformal radiotherapy." In Cancer Treatment and Research, 129–41. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-6121-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer - Radiotherapy treatment"

1

Sebaaly, Anthony, Corinne Bassile, Tamara Akl, Georges Farha, Jad El Barouky, Fares Azoury, and Sandy Rihana. "Radiotherapy Treatment Planning System Simulation Lung Cancer Application." In 2018 IEEE International Multidisciplinary Conference on Engineering Technology (IMCET). IEEE, 2018. http://dx.doi.org/10.1109/imcet.2018.8603054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Novikov, V. A., O. V. Gribova, R. V. Vasiljev, E. L. Choynzonov, V. I. Shtin, A. A. Shiianova, P. V. Surkova, Zh A. Starceva, and O. G. Shilova. "Intraoperative radiotherapy in combined treatment of sinonasal malignant tumors." In PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17). Author(s), 2017. http://dx.doi.org/10.1063/1.5001633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Griffiths, Gareth, Paul Cross, Simon Goldsworthy, Benjamin Winstone, and Sanja Dogramadzi. "Motion Capture Pillow for Head-and-Neck Cancer Radiotherapy Treatment." In 2018 7th IEEE International Conference on Biomedical Robotics and Biomechatronics (Biorob). IEEE, 2018. http://dx.doi.org/10.1109/biorob.2018.8487217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Phillips, Roger, James W. Ward, Pete Bridge, Rob M. Appleyard, and Andrew W. Beavis. "A hybrid virtual environment for training of radiotherapy treatment of cancer." In Electronic Imaging 2006, edited by Andrew J. Woods, Neil A. Dodgson, John O. Merritt, Mark T. Bolas, and Ian E. McDowall. SPIE, 2006. http://dx.doi.org/10.1117/12.650951.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Atoui, Hussein, David Sarrut, and Serge Miguet. "Usefulness of image morphing techniques in cancer treatment by conformal radiotherapy." In Medical Imaging 2004, edited by Robert L. Galloway, Jr. SPIE, 2004. http://dx.doi.org/10.1117/12.533009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wahl, Suzi, Tanisia De Carli Foletto, and Gerson Feldmann. "A Mathematical Model for the Estimation of Treatment Cost in Cancer Radiotherapy." In 2009 Third Southern Conference on Computational Modeling (MCSUL). IEEE, 2009. http://dx.doi.org/10.1109/mcsul.2009.24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Freed, Yakov. "Homeopathic Treatment Ameliorates Fatigue and Attentional Deterioration in Radiotherapy Breast Cancer Patients." In HRI London 2019—Cutting Edge Research in Homeopathy: Presentation Abstracts. The Faculty of Homeopathy, 2020. http://dx.doi.org/10.1055/s-0040-1702066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mzenda, Bongile, David J. Brown, and Alex Gegov. "Improving the transparency in fuzzy modelling of radiotherapy margins in cancer treatment." In 2011 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology - Part of 17273 - 2011 Ssci. IEEE, 2011. http://dx.doi.org/10.1109/cibcb.2011.5948453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Christensen, Gary E., Jeffrey F. Williamson, K. S. C. Chao, Michael I. Miller, F. B. So, and Michael W. Vannier. "Deformable anatomical templates for brachytherapy treatment planning in radiotherapy of cervical cancer." In Optical Science, Engineering and Instrumentation '97, edited by Robert A. Melter, Angela Y. Wu, and Longin J. Latecki. SPIE, 1997. http://dx.doi.org/10.1117/12.292779.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Singh, Nisha. "Cohort study of vulvar cancer cases over a period of 10 years." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685356.

Full text
Abstract:
Objective: To study the risk factors, management protocols and outcome of vulvar cancer cases over a period of 10 years in a tertiary care hospital. Methods: It is a retrospective cohort study of vulvar cancer from January 2004 to January 2014 at King George Medical University, Lucknow. Hospital records of 41 patients with histologically proven diagnosis of vulvar cancer were studied from Department of Obstetrics and Gynecology and Department of Radiotherapy. The presence of risk factors, stage of disease, treatment modalities used and disease outcome in terms survival were studied. The data collected was analyzed and compared with the published literature. Results: The mean age for diagnosis of vulvar cancer was 52 years and peak incidence was seen in age group of 50-70 years. Incidence was significantly more in multiparous (p = 0.001) and postmenopausal women (p = 0.007). An average of 4.1 cases were seen per year. 97.56% cases were squamous cell carcinomas including one case of verrucous carcinoma. Only one non-squamous case of Bowen’s disease was seen. 20 cases belonged to early stage (1 and 2) while 21cases had advanced disease (3 and 4). 48.78% cases were primarily treated with surgery, 26.83% with radiotherapy, 7.3% with chemotherapy and 17.07% with combined chemoradiation. 78% of surgically treated cases had mean survival of 5 years. Mean survival of 1 year was recorded in advanced disease cases. Limitation of the study was poor follow up after treatment. Conclusion: Incidence of vulvar cancer is significantly high in multiparous and postmenopausal women. Surgical treatment is the best option in early stage of disease (stage I and II) and gives high survival rates while advanced disease treated with chemoradiation has poor survival.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer - Radiotherapy treatment"

1

Chen, Lili. MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2005. http://dx.doi.org/10.21236/ada435143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Lili. MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2007. http://dx.doi.org/10.21236/ada468037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Leavitt, Dennis D., and David K. Gaffney. Optimization of Breast Cancer Treatment by Dynamic Intensity Modulated Electron Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada412101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Lili. MR-Guided Pulsed High-Intensity Focused Ultrasound Enhancement of Gene Therapy Combined With Androgen Deprivation and Radiotherapy for Prostate Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada518248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Lili. MR Guided Pulsed High Intensity Focused Ultrasound Enhancement of Gene Therapy Combined with Androgen Deprivation and Radiotherapy for Prostate Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada569443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer - Radiotherapy treatment' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography